4,4'-diaminobenzanilide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4,4'-diaminobenzanilide: not carcinogenic [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	69917
CHEMBL ID	350416
SCHEMBL ID	137276
MeSH ID	M0104515

Synonyms (47)

Synonym
nsc-37092
785-30-8
4-aminobenzoyl-4'-aminoanilide
benzamide, 4-amino-n-(4-aminophenyl)-
benzanilide,4'-diamino-
nsc37092
4,4'-diaminobenzanilide
4-amino-n-(4-aminophenyl)benzamide
p,p'-diaminobenzanilide
einecs 212-321-5
nsc 37092
benzanilide, 4,4'-diamino-
OPREA1_697167
4,4'-diaminobenzanilide, 98%
STK396695
CHEMBL350416
D2005
AKOS001037988
4-amino-n-(4-aminophenyl)benzamide;
A839439
BBL004104
00x4jm89uh ,
unii-00x4jm89uh
ccris 8916
dtxcid40400
NCGC00258270-01
dtxsid4020400 ,
tox21_200716
cas-785-30-8
FT-0616994
n-(4-aminophenyl)-4-aminobenzamide
diaminobenzanilide, 4,4'-
SCHEMBL137276
4,4'-diamino benzanilide
4-amino-n-(4-amino-phenyl)-benzamide
W-104276
4-amino-n-(4-aminophenyl)benzamide #
mfcd00025361
sr-01000363561
SR-01000363561-1
F10214
DS-14634
EN300-16815
Q27231382
4,4'-diaminobenzanilide (daba)
CS-W013005
Z56785539

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (10)

Potency Measurements

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Luciferase	Photinus pyralis (common eastern firefly)	Potency	39.9800	0.0072	15.7588	89.3584	AID1224835
RAR-related orphan receptor gamma	Mus musculus (house mouse)	Potency	11.4410	0.0060	38.0041	19,952.5996	AID1159521; AID1159523
AR protein	Homo sapiens (human)	Potency	51.4045	0.0002	21.2231	8,912.5098	AID1259243; AID743042; AID743054
estrogen receptor 2 (ER beta)	Homo sapiens (human)	Potency	15.3709	0.0006	57.9133	22,387.1992	AID1259377
progesterone receptor	Homo sapiens (human)	Potency	38.6100	0.0004	17.9460	75.1148	AID1346784
retinoic acid nuclear receptor alpha variant 1	Homo sapiens (human)	Potency	3.1114	0.0030	41.6115	22,387.1992	AID1159552; AID1159553; AID1159555
estrogen-related nuclear receptor alpha	Homo sapiens (human)	Potency	61.1927	0.0015	30.6073	15,848.9004	AID1224849
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a	Homo sapiens (human)	Potency	68.6594	0.0017	23.8393	78.1014	AID743083
Histone H2A.x	Cricetulus griseus (Chinese hamster)	Potency	63.6632	0.0391	47.5451	146.8240	AID1224845
histone deacetylase 9 isoform 3	Homo sapiens (human)	Potency	27.3338	0.0376	17.0823	61.1927	AID1259364; AID1259388
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (15)

Assay ID	Title	Year	Journal	Article
AID446991	Anticonvulsant activity in CF1 albino mouse assessed as inhibition of maximal electric shock-induced seizure at 100 mg/kg, ip after 0.5 hrs	2009	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17	In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID446996	Anticonvulsant activity in Sprague-Dawley rat assessed as inhibition of maximal electric shock-induced seizure at 30 mg/kg, po after 0.25 hrs	2009	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17	In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID446994	Anticonvulsant activity in CF1 albino mouse assessed as inhibition of maximal electric shock-induced seizure at 100 mg/kg, ip after 4 hrs	2009	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17	In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID446990	Anticonvulsant activity in CF1 albino mouse assessed as inhibition of maximal electric shock-induced seizure at 30 mg/kg, ip after 0.5 hrs	2009	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17	In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID446998	Anticonvulsant activity in Sprague-Dawley rat assessed as inhibition of maximal electric shock-induced seizure at 30 mg/kg, po after 1 hrs	2009	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17	In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID446995	Anticonvulsant activity in CF1 albino mouse assessed as inhibition of maximal electric shock-induced seizure at 300 mg/kg, ip after 4 hrs	2009	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17	In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID446997	Anticonvulsant activity in Sprague-Dawley rat assessed as inhibition of maximal electric shock-induced seizure at 30 mg/kg, po after 0.5 hrs	2009	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17	In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID447144	Neurotoxicity in Sprague-Dawley rat at 500 mg/kg, po by positional sense and gait and stance test	2009	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17	In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID345022	Binding affinity to human telomerase P2b RNA by STD NMR	2008	Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22	Discovery of ligands for a novel target, the human telomerase RNA, based on flexible-target virtual screening and NMR.
AID446993	Anticonvulsant activity in CF1 albino mouse assessed as inhibition of maximal electric shock-induced seizure at 30 mg/kg, ip after 4 hrs	2009	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17	In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID115839	Compound was tested for the number of control mice with decreased RBC to that of number of tested mice at 100 mg/kg p.o.; 0/10	1998	Bioorganic & medicinal chemistry letters, Jan-06, Volume: 8, Issue:1	Discovery of FR115092: a novel antinephritic agent.
AID446999	Anticonvulsant activity in Sprague-Dawley rat assessed as inhibition of maximal electric shock-induced seizure at 30 mg/kg, po after 2 hrs	2009	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17	In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID447000	Anticonvulsant activity in Sprague-Dawley rat assessed as inhibition of maximal electric shock-induced seizure at 30 mg/kg, po after 4 hrs	2009	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17	In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID446992	Anticonvulsant activity in CF1 albino mouse assessed as inhibition of maximal electric shock-induced seizure at 300 mg/kg, ip after 0.5 hrs	2009	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17	In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID117036	Inhibition of proteinuria in the graft-versus-host disease mice following 100 mg/kg p.o. administration.	1998	Bioorganic & medicinal chemistry letters, Jan-06, Volume: 8, Issue:1	Discovery of FR115092: a novel antinephritic agent.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (4)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1 (25.00)	18.7374
1990's	1 (25.00)	18.2507
2000's	2 (50.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.39

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	24.39 (24.57)
Research Supply Index	1.79 (2.92)
Research Growth Index	4.54 (4.65)
Search Engine Demand Index	23.28 (26.88)
Search Engine Supply Index	2.00 (0.95)

This Compound (24.39)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	5 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
dapsone [no description available]	1.99	1	substituted aniline; sulfone	anti-inflammatory drug; antiinfective agent; antimalarial; leprostatic drug
quetiapine [no description available]	2.04	1	dibenzothiazepine; N-alkylpiperazine; N-arylpiperazine	adrenergic antagonist; dopaminergic antagonist; histamine antagonist; second generation antipsychotic; serotonergic antagonist
p-aminoazobenzene p-Aminoazobenzene: Used in the form of its salts as a dye and as an intermediate in manufacture of Acid Yellow, diazo dyes, and indulines.. 4-(phenylazo)aniline : Azobenzene substituted at one of the 4-positions by an amino group. It has a role as a dye and an allergen.	1.96	1
4,4'-diaminodiphenylmethane 4,4'-diaminodiphenylmethane: RN given refers to parent cpd; structure. 4,4'-diaminodiphenylmethane : An aromatic amine that is diphenylmethane substituted at the 4-position of each benzene ring by an amino group.	2.05	1	aromatic amine	allergen; carcinogenic agent
di-(4-aminophenyl)ether di-(4-aminophenyl)ether: structure	2.42	2	aromatic ether
4,4'-thiodianiline 4,4'-thiodianiline: structure	2.42	2	substituted aniline
thioproperazine thioproperazine: was heading 1963-94; use PHENOTHIAZINES to search THIOPROPERAZINE 1966-94. thioproperazine : A phenothiazine derivative in which the phenothiazine tricycle has a dimethylaminosulfonyl substituent at the 2-position and a 3-(4-methylpiperazin-1-yl)propyl group at N-10.	2.04	1	N-alkylpiperazine; N-methylpiperazine; phenothiazines; sulfonamide	phenothiazine antipsychotic drug
4,4'-diaminoazobenzene 4,4'-diaminoazobenzene : Azobenzene substituted at each of the phenyl 4-positions by an amino group.	6.96	1
4,4'-diaminobenzophenone 4,4'-diaminobenzophenone: structure in first source	2.42	2
4,4'-Dihydroxybenzophenone [no description available]	2.04	1	benzophenones
LSM-5894 [no description available]	2.04	1	organic heterobicyclic compound; organonitrogen heterocyclic compound

Condition	Relationship Strength	Studies
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.42	2
Nephritis Inflammation of any part of the KIDNEY.	1.99	1
Anemia A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.	1.99	1
Absence Seizure [description not available]	2.05	1
Seizures Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.	2.05	1
Experimental Neoplasms [description not available]	1.96	1

chemdatabank.com